Volume : 13, Issue : 08, August – 2026

Title:

EVALUATION OF HYPOLIPIDAEMIC EFFECT OF HYDROETHANOLIC EXTRACT OF LEAVES OF MUSA PARADISICA (BANANA) IN HIGH FAT DIET FED WISTAR RATS

Authors :

Aman Kumar*, Radhika Patel

Abstract :

Lipid lowering effect of hydroethanolic extract of Musa paradisica leaves was evaluated in high fat diet induced hyperlipidemic models of wistar albino rats. Test extract inhibited the elevation in serum cholesterol and triglyceride levels on high fat diet administration rats. The extract at the same dose level significantly attenuated the elevated serum total cholesterol and triglycerides with an increase in high-density lipoprotein cholesterol in high-fat diet-induced hyperlipidemic rats. The standard drug Atrovastatin showed slightly better effects. In histopathological study it was found that treatment of test extractsignificantly decrease in the dilatations in the sinusoidal capillaries of the liver, cytoplasmic fatty infiltration, and granular degeneration when compared with the high-fat diet-fed group II animals. The outcome of the study reveals the lipid lowering activity of hydroethanolic extract of Musa paradisiac in dyslipidaemic conditions by interfering with the biosynthesis of cholesterol and utilization of lipids.
Keywords: Musa pradisica, antihyperlipidemic activity, High fat diet, HDL-C, Triglycerides.

Cite This Article:

Please cite this article in press Aman Kumar et al., Evaluation of Hypolipidaemic effect of Hydroethanolic extract of Leaves of Musa paradisica (banana) in High fat Diet fed wistar rats. Indo Am. J. P. Sci, 2026; 13(08).

REFERENCES:

1. Organization, W. H. (2000). The world health report 2000: health systems: improving performance. World Health Organization. Balunas, M. J., &Kinghorn, A. D. (2005). Drug discovery from medicinal plants. Life sciences, 78(5), 431-441.
2. Fabricant, D. S., & Farnsworth, N. R. (2001). The value of plants used in traditional medicine for drug discovery. Environmental health perspectives, 109(suppl 1), 69-75.
3. Heinrich, M., Ankli, A., Frei, B., Weimann, C., &Sticher, O. (1998). Medicinal plants in Mexico: Healers’ consensus and cultural importance. Social science & medicine, 47(11), 1859-1871.
4. Heinrich, M., Barnes, J., Prieto-Garcia, J., Gibbons, S., & Williamson, E. M. (2017). Fundamentals of pharmacognosy and phytotherapy E-BOOK. Elsevier Health Sciences.
5. Organization, W. H. (2000). The world health report 2000: health systems: improving performance. World Health Organization.
6. Ma, L. Y. (2018). Research progress on adverse reactions and non-cardiovascular effects of statins. Chin. Med. Guide (04), 8–9.
7. Tripathi, KD. “Hypolipidemic drugs and Plasma expanders”. Essentials of Medical Pharmacology, 1994, 3rd edition, New Delhi: Medical Publishers (P) Ltd., 575-586.
8. Singh S, Jain V, Jain Sk, Chandra K. Medicinal Plants And Phytochemicals In Prevention And Management Of Lifestyle Disorders: Pharmacological Studies And Challenges. Asian J Pharm Clin Res. 2021;14(12):1-6.
9. Manoj Jaybhaye et al; Evaluation of Hypolipidemic Potential of a Polyherbal Formulation in Experimental Rats. Research J. Pharm. and Tech. 2018, 11(11): 5037-5041.
10. Gajendra Kumar et al; The hypolipidemic activity of Ayurvedic medicine, Arogyavardhinivatiin Triton WR-1339-induced hyperlipidemic rats: A comparison with fenofibrate. Journal of Ayurveda & Integrative Medicine, 2013; 4(3): 165-170.
11. Ranjan Kumar Giri et al; Hypolipidemic effect of prepared Polyherbal formulations in Wistar albino rats. Research J. Pharm. and Tech. 2021, 14(8): 4314-4320.
12. A. K. Khanna, F. Rizvi, R. Chander. Lipid lowering activity of Phyllanthusniruri in hyperlipemic rats. Journal of Ethnopharmacology. 2002, 82:19-22.
13. Nitin Mahurkar et al; Antihyperlipidemic Effect of Polyherbal Formulation (PHF) in High Fat Diet Induced Hyperlipidemia. Research Journal of Pharmaceutical Dosage Forms and Technology. 2015, 7(1):11-14.
14. Repeated dose oral toxicity study in rodents, the organization for economic co-operation and development (oecd) guidelines for the testing of chemicals, OECD no 420.
15. XinyuJi et al; Bioactive compounds from herbal medicines to manage dyslipidemia. Biomedicine & Pharmacotherapy. 2019, 118:1-12.
16. Shivakumar S. Ladde&Bhusnure O. G. Evaluation of the hypolipidemic activity of polyherbal formulation through In-vivo and Insilico studies. International Journal of Health Sciences.2022, 6 (S3): 9831–9851.
17. ShyamSundar Shah et al; Formulation and Evaluation of Antidiabetic and Antihyperlipidemic Activities of Polyherbal Formulation in Streptozocin induced diabetic rat. Pharmaceutical and Biosciences Journal. 2019, 7(1): 26-30.
18. 10. Murali Mohan Reddy et al; Anti-hyperlipidemic effect of methanol bark extract of Terminalia chebula in male albino Wistar rats. Pharmaceutical Biology Early Online.2015:1-8.
19. Mustapha Tacherfiouta et al; Antihyperlipidemic effect of a Rhamnusalaternus leaf extract in Triton induced hyperlipidemic rats and human HepG2 cells. Biomedicine & Pharmacotherapy. 2018, 101: 501–509
20. SaritaKarole et al; Polyherbal Formulation Concept for Synergic Action: A Review. Journal of Drug Delivery & Therapeutics. 2019, 9(1-s):453-466.
21. Zobaer A. Mahmud & amp;Sitesh C. Bachar & amp; Nazmul Qais, Antihyperlipidemic activity of leaf and root extracts of Premnaesculenta (Roxb.) in Poloxamer-407 induced hyperlipidemic mice and rats. Oriental Pharmacy and Experimental Medicine. 2011:1-11
22. Hypolipidemic Activity Evaluation of DRF/AY/4013, an Herbal Formulation in Experimentally Induced Hyperlipidemic Rats. Journal of Complementary and Integrative Medicine. 2008,5(1):1-14.
23. Saravana A, Mazumder A & amp; Saravanan V S. Antihyperlipidemic activity of Camellia sinensis leaves in Triton WR-1339 induced albino rats. Phcog Mag. 2008, 4(60).
24. DadhaniaSagar et al; A Study of Anti-Hyperlipidemic Activity of Polyherbal Formulation Using Various Experimental Animal Models. Inventi Rapid, Ethanopharmacology. 2011, 2(1):1-4.
25. 17. Lachman L, Lieberman HA. The theory and practice of Industrial Pharmacy, 3rd edition. Varghese Publishing House, Bombay, 1990; 293-329.
26. V.Venkata Rajesham, D.V.R.N Bhikshapathi. Anti Hyperlipidemic Potential of Polyherbal Formulation in Wistar Albino Rats.International Journal of Pharmaceutical Sciences and Drug Research. 2018, 10(3): 144-149.
27. Preeti Tiwari. Evaluation of Antihyperlipidemic Potential of Amritarishta Prepared by Traditional and Modern Methods in Hyperlipidemic Rats. Research Journal of Pharmacognosy and Phytochemistry. 2013, 5(6): 315-319.
28. The Ayurvedic Formulary of India, Part-I. 2000, 1st edition, The Controller of Publications, Delhi, 6.
29. K. A. Rony et al; Hypolipidemic activity of Phellinusrimosusagainsttriton WR-1339 and high cholesterol diet induced hyperlipidemic rats. Environmental Toxicology and Pharmacology. 2014, 37: 482-492.
30. Yuvraj Singh Surana et al; Evaluation of Antidiabetic, Hypolipidemic And Antioxidant Activity Of Polyherbal Formulation In Streptozotocin-Nicotinamide Induced Diabetes In Rats. International Journal of Pharmacy and Pharmaceutical Sciences. 2017, 9 (10): 105-110.
31. Mohammad A. Alzohairy et al; Therapeutics Role of Azadirachtaindica(Neem) and Their Active Constituents in Diseases Prevention and Treatment. Evidence-Based Complementary and Alternative Medicine. 2016:1-11.
32. FatemehYarmohamaddi et al; The Protective effect of Azadirchataindica (neem) against metabolic syndrom: A review. Iranian Journal of Basic Medical Sciences. 2021, 24(3):280-292.
33. AlirezaSadeghipour et al; Lipid Lowering Effect of PunicagranatumL. Peel in High Lipid Diet Fed Male Rats. Evidence-Based Complementary and Alternative Medicine.2014:1-5.
34. Thamolwan Suanarunsawat et al; Lipid-Lowering and Antioxidative Activities of Aqueous Extracts of Ocimum sanctum L. Leaves in Rats Fed with a High-Cholesterol Diet. Oxidative Medicine and Cellular Longevity.2011:1-9.
35. V. Maruthappan& K. Sakthi Shree, Hypolipidemic Activity Of Haritaki (TerminaliaChebula) In Atherogenic Diet Induced Hyperlipidemic Rats. Journal of Advance Pharmaceutical Technology & Research. 2010, 1 (2): 229-235.
36. 28. Gaber El-Saber Batiha et al; Chemical Constituents and Pharmacological Activities of Garlic (Allium sativum L.): A Review. Nutrients, 2020, 12(872): 1-21.
37. Rajesh N. Medicinal benefits of Musa paradisiaca (Banana). International Journal of Biology. 2017 Apr;2(2):51-4.
38. Adesola R. The pharmacological potentials of Musa paradisiaca Linn. Plant Science Today. 2022;8(4):1091-7.
39. Gaisamudre KN, Sarwade PP, Sonwani K, Chand S, Goswami M, Kaur H, Pant NC. Musa ParadisiacaIt’sPhytochemistry, Traditional Uses And Pharmacological Activities. Asian Journal of Pharmaceutical Research and Development. 2025 Dec 15;13(6):273-85.
40. Asuquo EG, Udobi CE. Antibacterial and toxicity studies of the ethanol extract of Musa paradisiaca leaf. Cogent Biology. 2016 Dec 31;2(1):1219248.
41. Karuppiah P, Mustaffa M. Antibacterial and antioxidant activities of Musa sp. leaf extracts against multidrug resistant clinical pathogens causing nosocomial infection. Asian Pacific journal of tropical biomedicine. 2013 Sep 1;3(9):737-42.
42. Ponmurugan Karuppiah PK, Muhammed Mustaffa MM. Antibacterial and antioxidant activities of Musa sp. leaf extracts against multidrug resistant clinical pathogens causing nosocomial infection.
43. Oyeyinka BO, Afolayan AJ. Comparative and correlational evaluation of the phytochemical constituents and antioxidant activity of Musa sinensis L. and Musa paradisiaca L. fruit compartments (Musaceae). The Scientific World Journal. 2020;2020(1):4503824.
44. Mbagwu H, Jackson C, Ekpo M, Okopedi E, Anah V, Ugwu C. Gastroprotective effects of ethanolic leaf extract of Musa paradisiaca L.(Musaceae) in rats.
45. Venkatesh KV, Kumar KG, Pradeepa K, Kumar SS, Vijay K. Anthelmintic activity of Musa paradisiaca (L.) cv. Puttabale. Int J Pharm Sci Drug Res. 2013 Jun 5;5:67-9.

Volume : 13, Issue : 08, August – 2026

Title:

EVALUATION OF ANTIHYPERLIPIDEMIC ACTIVITY OF SAPINDUS EMARGINATUS IN RATS

Authors :

Chinthala Jamima*, Dr.R.narasimha Rao, Dr.N. Raghunandhan

Abstract :

Obesity and hyperlipidemia have become major disorders predominantly causing prevailing cardiovascular diseases and ultimately death. The prolonged use of anti-obesity drugs and statins for reducing obesity and blood lipid levels is leading toward adverse effects of kidneys and muscles, specifically rhabdomyolysis. The objective of this study is to evaluate potential of seeds of Sapindus emarginatus against hyperlipidemia. In this model of Hyperlipidemia, 30 adult male wistar rats (200-250gms) were evenly divided into 5 groups in both groups. Group-1 and Group-2 served as untreated and model controls respectively, while Group-3, 4 and 5 were the treatments groups which were simultaneously treated with standard, 100 and 200 mg/kg extract respectively along with High Fat Diet. On last day, blood samples for biochemical parameters, were obtained under inhaled diether anaesthesia. The outcomes of this study were expressed as mean standard error and data were evaluated by using analysis of variance followed by multiple comparisons. Oral administration of 100 mg/ kg and 200mg/kg body weight of Methanolic extract residual fraction of Moringa oleifera. Leaves exhibited a significant reduction (P < 0.01) in serum lipid parameters such as triglycerides, total cholesterol, low density lipoprotein (LDL), very LDL and increase in high density lipoprotein in hyperlipidemic rats when compared with hyperlipidemic control in both models. Our results demonstrated that Methanolic extract fraction of Sesbania grandiflora. Possessed significant antihyperlipidemic activity.
Keywords: Sesbania grandiflora, Cholesterol, LDL, triglycerides and antihyperlipidemic activity.

Cite This Article:

Please cite this article in press Chinthala Jamimaet al., Evaluation of Antihyperlipidemic activity of Sapindus Emarginatus in rats,, Indo Am. J. P. Sci, 2026; 13(08).

REFERENCES:

1. Amit G, Vandana S, Sidharth M. HYPERLIPIDEMIA: An Updated Review. Inter J of Biopharma & Toxicol Res 2011;1:81-89.
2. Virchow RP, Thrombose IG. In Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. Frankfurt-am-Main, Meidinger Sohn & Company 1856, S 458-564.
3. Ankur rohilla, Nidhi Dagar, Seema Rohilla, Amarjeet Dahiya, Ashok Kushnoor. HYPERLIPIDEMIA- a deadly pathological condition. Inter J Curr Pharma Res 2012;4:15-18
4. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976;295:369-77.
5. Grundy SM, Vega GL. Hypertriglyceridemia: causes and relation to coronary heart disease – Semin. Thromb. Hemost 1988;14:249-64.
6. Dargel R. Lipoproteins and the etiopathogenesis of atherosclerosis. Zentralbl Allg Pathol 1989; 135: 501-504.